• Molecular NamePyridostigmine
  • SynonymPyridine N-Oxide; Pyridostigmine Bromide; Pyridostigmine Bromine; Pyridostigminum
  • Weight181.215
  • Drugbank_IDDB00545
  • ACS_NO155-97-5
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-3.57
  • pkaN/A
  • LogD (pH=7, predicted)-3.57
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.39
  • LogSw (predicted, AB/LogsW2.0)153.98
  • Sw (mg/ml) (predicted, ACD/Labs)443.09
  • No.of HBond Donors0
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds2
  • TPSA33.42
  • StatusFDA approved
  • AdministrationOral, intravenous
  • PharmacologyA parasympathomimetic and a reversible cholinesterase inhibitor.
  • Absorption_valueN/A
  • Absorption (description)Since it is a quaternary amine, it is poorly absorbed in the gut and doesn't cross the blood-brain barrier, except possibly in stressful conditions.
  • Caco_2N/A
  • Bioavailability7.6
  • Protein binding0.0
  • Volume of distribution (VD)1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHydrolysis by cholinesterases and by liver.
  • Half life0.3~2 h, increased in subjects with renal disease.
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A